Nivolumab plus gemcitabine-cisplatin vs gemcitabine-cisplatin alone for previously untreated unresectable or metastatic urothelial carcinoma: results for cisplatin-eligible patients in the phase 3 CheckMate 901 trial substudy
| Title | Nivolumab plus gemcitabine-cisplatin vs gemcitabine-cisplatin alone for previously untreated unresectable or metastatic urothelial carcinoma: results for cisplatin-eligible patients in the phase 3 CheckMate 901 trial substudy |
|---|---|
| Description | Abstract for ESMO 2023 |
| Organism | Homo sapiens |
| Data Type | Biomarker Data |
| Data Accessibility | Controlled-access |
| BioProject | PRJCA018901 |
| Release Date | 2023-10-24 |
| Submitter | Dingwei Ye (fuscc2012@163.com) |
| Organization | Fudan University Shanghai Cancer Center |
| Submission Date | 2023-08-30 |
HTTP download speed may be slow. It is highly recommended that you download the dataset using a dedicated FTP tool (such as FileZilla Client).
| File ID | File Title | Number/Samples | File Type | File Size | File Suffix | Download Times | Download |
|---|---|---|---|---|---|---|---|
| OMIX004824-01 | CA209-901 Abstract of ESMO 2023 | 310 | Biomarker Data | 39.3 KB | 0 | Controlled |